ArticleDiscover oncology2025
Silencing hnRNPD inhibits gastric cancer growth by increasing TXNIP-mediated oxidative stress.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gene dependency-informed inference of response to targeted cancer therapies.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRNA-binding proteins (RBPs) are essential for controlling gene expression, and their dysregulation is a key factor in tumor development and progression. Heterogeneous nuclear ribonucleoprotein D (hnRNPD), a member of the hnRNP family of RBPs, is aberrantly expressed in various tumors. However, its role and underlying mechanisms in gastric cancer have not been determined.
methodsThe expression patterns of hnRNPD in gastric cancer were analyzed using publicly available datasets and clinical specimens. The effects of hnRNPD on gastric cancer cell growth were assessed using the Cell Counting Kit-8 (CCK-8) and colony formation assays. Target genes regulated by hnRNPD were identified through RNA sequencing (RNA-seq) and RNA immunoprecipitation sequencing (RIP-seq).
resultsElevated expression of hnRNPD was observed in gastric cancer, and this overexpression was associated with an unfavorable prognosis. Knocking down hnRNPD could suppress the growth of gastric cancer cells and enhance endogenous oxidative stress. Thioredoxin-interacting protein (TXNIP) was identified as a downstream target of hnRNPD. Further analysis confirmed that hnRNPD diminished TXNIP expression by binding to and destabilizing its mRNA. Moreover, silencing TXNIP reversed the decrease in cell growth and the increase in oxidative stress caused by hnRNPD knockdown.
conclusionOur study highlights hnRNPD as a major contributor to gastric carcinogenesis. The knockdown of hnRNPD hinders gastric cancer growth by directly interacting with TXNIP, promoting its expression, and inducing oxidative stress. These findings suggest that hnRNPD may serve as a valuable target for the treatment of gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.